Article
Disrupted copper availability in sporadic ALS: Implications for Cu <sup>II</sup> (atsm) as a treatment option
2020-04-18
Abstract excerpt
<h4>ABSTRACT</h4> <h4>Objective</h4> The copper compound Cu II (atsm) is in phase 2/3 testing for treatment of the neurodegenerative disease amyotrophic lateral sclerosis (ALS). Cu II (atsm) consistently and reproducibly ameliorates neurodegeneration in mutant SOD1 mouse models of ALS where its neuroprotective activity has been ascribed in part to improving availability of copper to essential cuproenzymes. How...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- aa91b24e-d79d-5b59-af35-97f32f328073
- DOI
- 10.1101/2020.04.17.047704
